AbbVie Inc. (ABBV)
AbbVie inks immune disorder drug licensing deal with China's FutureGen
U.S. drugmaker AbbVie will develop and commercialize an experimental treatment for inflammatory bowel disease (IBD) from China's FutureGen Biopharmaceutical under a licensing agreement, the companies said on Thursday.
AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
AbbVie, Inc. (NYSE:ABBV ) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercial Officer Roopal Thakkar - SVP & Chief Medical Officer, Global Therapeutics Scott Reents - EVP & CFO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Welcome everybody. Glad that you can join us.
Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts
When it comes to targeting discounted ideas in the equities sector, undervalued blue-chip stocks offer some of the most compelling prospects. First and foremost, blue chips earn the status through decades of business and earnings expansion.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie (ABBV) Laps the Stock Market: Here's Why
AbbVie (ABBV) closed the most recent trading day at $170.46, moving +0.61% from the previous trading session.
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Top 2 dividend stocks to buy for long-term gains
Dividend stocks benefit from falling interest rates as money managers shift to income-oriented equities with yields above the S&P 500.
Focus: AbbVie's tight grip on Humira market raises concerns about biosimilars
AbbVie's top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
AbbVie said on Thursday its therapy to treat patients with a type of ovarian cancer has met the main goal of a mid-stage trial.
Hedge Fund Favorites: 7 Stocks to Buy When You're Feeling Jittery
With the market entering a historically challenging season (due to the adage buy in May and go away), jittery investors may want to turn to stocks to buy tacitly endorsed by the hedge funds and other institutional players. Basically, if the big dogs like these ideas, you might want to consider adding some yourself.
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that provide life-changing drugs.
